A biopharmaceutical company that makes medicines for inflammatory diseases, including ARCALYST, the first and only FDA-approved therapy for recurrent pericarditis, a painful swelling of the sac around the heart. Kiniksa was founded in 2015 by a group of former colleagues from an earlier biotech firm who reunited to keep developing treatments for rare conditions. The name Kiniksa is an invented, distinctive-sounding corporate word with no traditional meaning.
Select a row to see that insider’s individual transactions. † Sum of the holdings confirmed in the 12 months before this insider's last filing. A Form 4 reports a holding per line — held directly, or through a named trust, partnership or foundation, and in each share class separately — never a person’s total. Lines not restated in that time are left out and shown apart: an active filer restates what they still hold, so a line they did not restate is more often an entity since renamed, whose shares a successor line reports too. An amber marker means some were left out.
Net open-market activity over the last 6 months: -730.0K shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.